Manipal Health Enterprises Limited MANIPALHOS NSEPHARMA
Company Overview
Manipal Health Enterprises Limited operates hospitals in India. The company offers services, such as multi-specialty tertiary and quaternary care through its network of hospitals. Its services include accident and emergency care, cancer care, cardiology, organ transplants, obstetrics and gynaecology, neurology, nephrology, orthopaedics, proctology, rheumatology, and urology. The company also offers medical services, including robotic spine surgery, bariatric surgery, head and neck surgery, liver transplantation, dialysis, laparoscopic surgery, organ transplant, orthopaedic robotic surgery, spine care, and clinics for conditions like epilepsy, chronic pain, and diabetes. In addition, it offers home care, a woman's and childcare centre, an insurance helpdesk, and international patient services, diagnostic services, pharmacy sales, home healthcare, teleconsultations, e-pharmacy, and digital health solutions. Further, it delivers outpatient treatment, diagnostics, and advanced clinical care through its hospital network, and collaborates with foundations and NGOs to offer healharmathcare services to underserved populations. The company was formerly known as Manipal Health Enterprises Private Limited and changed its name to Manipal Health Enterprises Limited in December 2025. The company was founded in 1991 and is headquartered in Bengaluru, India.
Why Investors Should Care
Revenue has grown at a 34.1% CAGR over the past five years.
Operating margin of 17.8% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹10,935.62 Cr (+18.0% YoY); net profit ₹654.93 Cr.
- Trailing 12 Months Year-on-year growth — revenue +38.1%, earnings -9.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.1%, profit CAGR 5.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.12% |
| 1 Year: | 38.10% |
Compounded Profit Growth
| 5 Years: | 4.98% |
| 1 Year: | -9.70% |
Stock Price Performance
| 1 Year: | -5.91% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -15.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)31.94 · Neutral
P/E of 129.21 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 129.2.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MANIPALHOS Manipal Health Enterprises Limited NSEPHARMA | 627.55 | 129.21 | ₹82,263.69 Cr | 0.00% | 9.83% | 7.77% | 34.12% | 4.98% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 6,079.39 Cr | 9,263.56 Cr | 10,935.62 Cr |
| Cost of Revenue | 3,443.55 Cr | 3,280.45 Cr | 3,838.29 Cr |
| Gross Profit | 2,635.84 Cr | 5,983.10 Cr | 7,097.33 Cr |
| Operating Expenses | 1,311.43 Cr | 4,241.86 Cr | 5,101.51 Cr |
| Operating Income | 1,324.41 Cr | 1,741.24 Cr | 1,995.82 Cr |
| EBITDA | 1,546.86 Cr | 2,455.03 Cr | 2,834.87 Cr |
| Interest Expense | 404.81 Cr | 1,141.84 Cr | 1,154.39 Cr |
| Pretax Income | 745.04 Cr | 731.62 Cr | 959.68 Cr |
| Tax Provision | 211.83 Cr | 196.82 Cr | 274.78 Cr |
| Net Income | 594.32 Cr | 512.96 Cr | 654.93 Cr |
| Diluted EPS | 4.52 | 3.90 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Total Assets | 10,818.83 Cr | 21,443.81 Cr | 24,864.50 Cr |
| Current Assets | 2,057.95 Cr | 4,053.26 Cr | 4,109.00 Cr |
| Cash & Equivalents | 360.88 Cr | 976.96 Cr | 299.35 Cr |
| Inventory | 103.18 Cr | 150.40 Cr | 169.85 Cr |
| Receivables | 458.88 Cr | 731.97 Cr | 929.76 Cr |
| Total Liabilities | 6,731.32 Cr | 15,283.52 Cr | 16,065.74 Cr |
| Current Liabilities | 1,656.74 Cr | 2,734.54 Cr | 3,362.37 Cr |
| Long Term Debt | 3,700.14 Cr | 9,725.70 Cr | 9,948.81 Cr |
| Total Debt | 5,130.24 Cr | 11,900.83 Cr | 12,863.06 Cr |
| Total Equity | 4,015.53 Cr | 5,820.04 Cr | 8,426.09 Cr |
| Shares Outstanding | - | - | - |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating Cash Flow | 1,388.64 Cr | 1,569.83 Cr | 2,078.40 Cr |
| Investing Cash Flow | -870.50 Cr | -2,658.34 Cr | -7,036.74 Cr |
| Financing Cash Flow | -250.21 Cr | 904.08 Cr | 4,954.44 Cr |
| Capital Expenditure | -331.94 Cr | -1,054.31 Cr | -1,316.19 Cr |
| Free Cash Flow | 1,056.71 Cr | 515.52 Cr | 762.21 Cr |
| Net Change in Cash | 267.94 Cr | -184.43 Cr | -3.90 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Gross Margin % | 43.4% | 64.6% | 64.9% |
| Operating Margin % | 21.8% | 18.8% | 18.3% |
| Net Margin % | 9.8% | 5.5% | 6.0% |
| ROE % | 14.8% | 8.8% | 7.8% |
| ROCE % | 14.5% | 9.3% | 9.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MANIPALHOS
Price performance - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBnUThLb2VMWkdfOXgtLUFFSWdSaTlpUm42Q3Yzb1FWSC1JZlFpYUtBWVlfSkp3cmF2WHZnWUxoUHZxcFctdE5zRndBWUZxbmthZkhqUHBHQ1N0VmtfT1J3?oc=5" target="_blank">Price performance</a> <font …
MANIPALHOS Share Price Today - Manipal Health Enterprises Stock Analysis - Equitypandit
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9NcUJfcEt4OW0ta292MGpOZkNCaG9NRGxkR2dkTFVEc0lGSVpZaEN5YkFCUF9JX245SmRGRmdJMUJDWndfTGtrdzZOaDd3azQ3MVUzM2FlVHRzYVI3TjRYdw?oc=5" target="_blank">MANIPALHOS Share Price Today - Manipa…
MANIPAL HEALTH ENTERPRI L Share Price After Fresh Yearly Low - Univest
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOZzFfbmd1VnRHREZSXzBkZ3hCSkpyQ2FPbjlxR2lRTEJ0bEFDSHNmbmVHR2xyQ2FRTk16d1RDTlBPN1ZHdGxRNV9OVDVua25uZUJ1Q3JJWWc3V3ZqYkRXcUwwa0pTdV9zR3ZzaUM2VFZhNGlObk56SmxsbncwX3NwR0Vwamk2OEdOMVA1V0…
MANIPALHOS Exposed! Unveiling the Hidden Strengths and Weaknesses of This Healthcare Stock - MarketSmith India
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRFEtTER3MC1DWXR5SFlWb2hOc0V5UDdPR09scloxYnh6cmFVYUFMejg5eXg0S3ZTM1k4czdWblJXOEpuZmQyWTVfNlpFN01ZRFRXd0pxN3VwNFpUdVRhWG00Z0tiZ1NqSTNnd21HUVVzR2ktNGQ0NlhJUkJpc1FWRkJ5dHl6Nm5U?oc=5"…
MANIPALHOS Share Price near 52-week low: price, RSI view - Univest
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQRkxrakp5M0ZFMF8zQ1ZHMV9pc25wbUg2OXNNek55M2YxM2RPZEI0R3lycUtQdzd6bFJGdzY0SUV2ejlNVHNhODBfc3NHN2ZMclpJX3JXMmtGMzVoMmNmbGszeGppSktJRS1xbm9CSVhOM2VkSndycmVLRm8wa1dYdVRLU2JhNWh5aElndj…
Manipal Health Enterprises (NSEI:MANIPALHOS) - Stock Analysis - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPblg2cTlfNUV0WFJnaTBNM2dVeDVmQ3ZOeFlBZkFSTjdLd1F0N0JkXzIyb2w1R0lUMkhvSjZUSGYwZkVJZHZFUHlOcGtsMDAzRUNtWHJVZU5wci05dkFTVjNvTVI0X2oybm1SeUhxMDJfUXZaRnBvS3lBNV9yWHVvUk9keDYzT0k0OURsOX…
MANIPALHOS — Frequently Asked Questions
What is the current share price of Manipal Health Enterprises Limited (MANIPALHOS)?
As of 2026-10-23 04:58 IST, Manipal Health Enterprises Limited (MANIPALHOS) trades at ₹627.55 on NSE. Its 52-week range is ₹627.55 to ₹797.95.
What is the market capitalisation of MANIPALHOS?
Manipal Health Enterprises Limited (MANIPALHOS) has a market capitalisation of ₹82,263.69 Cr on NSE.
What is the P/E ratio of MANIPALHOS?
MANIPALHOS trades at a trailing price-to-earnings (P/E) ratio of 129.21. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 8.76.
What is the return on equity (ROE) of MANIPALHOS?
MANIPALHOS has a return on equity (ROE) of 7.77%. Its return on capital employed (ROCE) is 9.83%.
Is MANIPALHOS a good stock to buy?
This page provides a data-driven analysis of Manipal Health Enterprises Limited (MANIPALHOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.